Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 9/20 | 0.47 |
| ▸ | NPY1R | P25929 | 5/20 | 0.47 |
| ▸ | NPY2R | P49146 | 4/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | RXFP4 | Q8TDU9 | 1/20 | 0.43 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9346849 | 0.95 | RXFP1 (0.52) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9346837 | 0.95 | RXFP1 (0.52) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31670473 | 0.94 | ENPEP (0.48) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31670487 | 0.94 | ENPEP (0.48) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31670471 | 0.93 | RXFP1 (0.46) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29415983 | 0.90 | NPY4R (0.51) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30764137 | 0.90 | RXFP1 (0.54) | RXFP1KEAP1BACE1 | |
| SCHEMBL29736187 | 0.90 | ENPEP (0.47) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL10168783 | 0.90 | RXFP1 (0.49) | RXFP1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30389981 | 0.89 | RXFP1 (0.55) | RXFP1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332261-A1 | Payload-Polymer-Protein Conjugates | GLYKOS FINLAND OY (FI) | 2025-10-30 | — | — | US | disclosed |
| EP-3166638-B1 | PAYLOAD-POLYMER-PROTEIN CONJUGATES | GLYKOS FINLAND OY (FI) | 2025-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332261-A1 | Payload-Polymer-Protein Conjugates | TXLNA, DDOST, CD44 | RXFP1 3397/4885NPY4R 2312/4885NPY1R 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.